You are here
Patient Enrollment Complete in Phase 3 Study of Vandetanib in Non-Small Cell Lung Cancer
ZEST is a randomized, double-blind, multi-center Phase III study to assess the efficacy of vandetanib versus erlotinib in overall survival (OS) and progression-free survival (PFS) in over 1,150 patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line anti-cancer therapy.
"Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.
ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.
The other studies are:
- ZODIAC (vandetanib + docetaxel versus docetaxel alone)
- ZEAL (vandetanib + pemetrexed versus placebo + pemetrexed); and,
- ZEPHYR (vandetanib + best supportive care (BSC) versus placebo + BSC).
The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel). (1)(2) Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this indication.